title: Treatment of advanced leukemia in mice with mRNA engineered T cells.
abstract: Cytotoxic T lymphocytes (CTLs) modified with chimeric antigen receptors (CARs) for adoptive immunotherapy of hematologic malignancies are effective in preclinical models and are being tested in several clinical trials. Although CTLs bearing stably expressed CARs generated by integrating viral vectors are efficacious and have potential long-term persistence, this mechanism of CAR expression can potentially result in significant toxicity. T cells were electroporated with an optimized in vitro transcribed RNA encoding a CAR against CD19. These RNA CAR CTLs were then tested in vitro and in vivo for efficacy. We found that T cells expressing an anti-CD19 CAR introduced by electroporation with optimized mRNA were potent and specific killers of CD19 target cells. CD19 RNA CAR T cells given to immunodeficient mice bearing xenografted leukemia rapidly migrated to sites of disease and retained significant target-specific lytic activity. Unexpectedly, a single injection of CD19 RNA CAR T cells reduced disease burden within 1 day after administration, resulting in a significant prolongation of survival in an aggressive leukemia xenograft model. The surface expression of the RNA CARs may be titrated, giving T cells with potentially tunable levels of effector functions such as cytokine release and cytotoxicity. RNA CARs are a genetic engineering approach that should not be subject to genotoxicity, and they provide a platform for rapidly optimizing CAR design before proceeding to more costly and laborious stable expression systems.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Barrett
authors.forename: Yangbing
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Liu
authors.forename: Shuguang
authors.initials: S
authors.lastname: Jiang
authors.forename: Carmine
authors.initials: C
authors.lastname: Carpenito
authors.forename: Michael
authors.initials: M
authors.lastname: Kalos
authors.forename: Richard G
authors.initials: RG
authors.lastname: Carroll
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000235:genetics; D015153:Blotting, Western; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D018274:Electroporation; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D058851:GPI-Linked Proteins / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive; D016086:Lentivirus / Q000235:genetics; D000090204:Mesothelin; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D011946:Receptors, Antigen / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics; D013601:T-Lymphocytes / Q000378:metabolism / Q000637:transplantation*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D047368:Tumor Burden / Q000276:immunology; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D018941:Antigens, CD19; D058851:GPI-Linked Proteins; D012333:RNA, Messenger; D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins; D000090204:Mesothelin